Participating Institutions & Investigators

Maysa Abu-Khalaf, M.D., M.B.A., is a Professor and Executive Vice Chair in the Department of Medical Oncology at Thomas Jefferson University, serves as Enterprise Director of the Women’s Cancer Center of Excellence, and is a valued member of the ABRCC consortium. She is a breast medical oncologist with a clinical and research focus on the management of early-stage and metastatic breast cancer, and cancer survivorship. She is actively involved in the design and conduct clinical trials evaluating novel approaches to improve patient outcomes.

Dr. Abu-Khalaf’s research interests include advancing treatment strategies for breast cancer and identifying new ways to predict and improve response to therapy. Most recently, in July 2026, she co-authored a study evaluating an innovative 3D ultrasound-based approach to predict breast cancer response to neoadjuvant chemotherapy. Her recent work also includes research evaluating novel combination therapies for hormone receptor-positive, HER2-negative advanced breast cancer and identifying predictive markers of response to endocrine therapy in combination with CDK 4/6 inhibitors.

Dr. Abu-Khalaf received her medical degree from the University of Jordan School of Medicine, completed her residency training at the Yale University affiliated-Norwalk Hospital Internal Medicine Program and her Medical Oncology fellowship at Yale University. She is board certified in Medical Oncology.

Dr. Shagisultanova is a breast medical oncologist and physician scientist. Her clinical and translational research efforts are dedicated to improving outcomes of breast cancer patients through development of novel treatments and overcoming challenges posed by drug resistance. She currently leads an Enterprise Breast Medical Oncology program at Thomas Jefferson University, Philadelphia, PA.

Dr. Shagisultanova has extensive clinical and research training and oncology work experience. After obtaining MD and PhD degrees in her native Russia, she relocated to the US for postdoctoral studies in cancer genomics at Sanford Burnham Medical Research Institute in San Diego and subsequently completed clinical research training at the University of California, San Diego. She completed her residency at the UCSF Health Stanyan Hospital, and hematology-oncology fellowship at Fox Chase Cancer Center.

Prior to accepting a leadership position at Thomas Jefferson University, she worked for 10 years as a faculty at the University of Colorado Cancer Center, where she specialized in breast cancer in young women, HER2-positive breast cancer, CNS metastases, and resistance to targeted agents. She is a recipient of multiple research awards from the American Cancer Society, NCI / NCATS, NIH and DOD, as well as competitive grants from industry. She has led two investigator-initiated national clinical trials for patients with HER2+ breast cancer conceived from the groundwork of her translation laboratory. Her lab is currently investigating the molecular interactions between HER2 and PI3K.

Steve Manobianco Jr., M.D. is an Assistant Professor of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health in Philadelphia, Pennsylvania. His clinical sub-specialization is in breast cancer and cancer genetic risk assessment, including the management of individuals with hereditary cancer syndromes (especially HBOC syndrome) and elevated cancer risk without a specific germline genetic mutation.

Dr. Manobianco Jr.’s research interests include therapeutic interventional clinical trials as well as the utilization of novel technologies to promote precision medicine and targeted therapy delivery in breast cancer. 

Jefferson University Hospitals and Thomas Jefferson University are partners in providing excellent clinical and compassionate care for our patients in the Philadelphia region, educating the health professionals of tomorrow in a variety of disciplines and discovering new knowledge that will define the future of clinical care. Jefferson has topped the list of hospitals in Pennsylvania (3rd) and the Philadelphia metro area (2nd) in U.S.News & World Report’s annual listing of the best hospitals and specialties. Learn more at: http://hospitals.jefferson.edu/about-us.html.

Dr. Brown-Glaberman holds a Doctor of Medicine from The University of New Mexico School of Medicine where she also completed a research fellowship in the Department of Pathology. She completed her internship, residency and hematology / oncology fellowship at the University of Arizona in Tucson, Arizona. Dr. Brown-Glaberman returned to her home state and to the University of New Mexico Comprehensive Cancer Center in 2013. Her interests are centered on the treatment of solid tumors, particularly breast cancer. Her research focuses on the development of prognostic and predictive biomarkers to guide the use of novel therapies. She co-leads the Breast Cancer Clinical Working Group and leads the Breast Protocol Development Subgroup at the UNM Cancer Center. Dr. Brown-Glaberman actively participates in NCI-sponsored clinical trials and is the Institutional Principal Investigator for numerous NCI cooperative group studies. Since her arrival in 2013, Dr. Brown-Glaberman has also driven the UNM Cancer Center Breast Clinical Working Group investigator-initiated clinical trial efforts.

CHRISTUS Health, a Catholic health ministry, will be a leader, a partner and an advocate in the creation of innovative health and wellness solutions that improve the lives of individuals and communities so that all may experience God’s healing presence and love.  What we are striving to do: CHRISTUS Health, past and present, has always been a leader, a partner and an advocate in the creation of innovative health and wellness solutions that improve the lives of individuals and communities. The world we live in is rapidly changing. Day in and day out as we go about living our lives it can be so easy to lose sight of fundamental issues that heavily impact our society. We are still fighting to rid the world of poverty and income inequality, caring for illness and chronic disease, and a myriad of challenges that threaten the welfare of women, children, the elderly and the underserved. There is so much work to be done which is why the history of our organization and the efforts of our sponsoring congregations is as relevant and important today as it ever was.  Our Values: With every life we impact, our ultimate goal is to utilize our values to provide the best care possible.

• Dignity: Respect for the worth of every person, recognition and commitment to the value of diverse individuals and perspectives, and special concern for the poor and underserved.
• Integrity: Honesty, justice, and consistency in all relationships.
• Excellence: High standards of service and performance.
• Stewardship: Wise and just use of talents and resources in a collaborative manner.
• Compassion: Service in a spirit of empathy, love and concern.

Learn more at: https://www.christushealth.org/connect/mission

Dr. Reva Basho is the Director of the Women’s Cancer Program at the Ellison Medical Institute. She is a breast medical oncologist and an assistant professor of medicine. Dr. Basho has authored more than 50 research articles, book chapters, and abstracts. She is active in national organizations including the American Society of Clinical Oncology, American Association for Cancer Research, and the Southwest Oncology Group, and she currently serves as a member of the National Cancer Institute’s working group for neoadjuvant clinical endpoints. Dr. Basho is also passionate about mentoring medical students and trainees. Alongside her clinical practice, Dr. Basho is a respected and nationally recognized clinical investigator. Her research focuses on the development of novel therapies for the treatment of high-risk breast cancers. Her specific interests include targeting the PI3K pathway and the development of novel immune therapies. She has served as the PI of numerous clinical trials and is currently leading a sub-study of the National Cancer Institute’s ComboMATCH trial.  Prior to the Institute, Dr. Basho served as the Co-Director of the Women’s Cancer Research Program at Cedars-Sinai. She received her undergraduate training at Rice University and her medical degree from Baylor College of Medicine. She completed her internal Medicine residency at UCLA Medical Center and her Hematology and Oncology fellowship at MD Anderson Cancer Center. 

The Ellison Medical Institute strives to spark innovation, leverage technology, and drive interdisciplinary, patient-centered research to continually enhance health, reimagine and redefine cancer care, and transform lives. Established in 2016 as a medical research and development center, the Institute features innovation labs for artificial intelligence and molecular analytics and was among the first organizations to vertically integrate the interdisciplinary study and treatment of disease. We offer multifaceted programs, including a preventative medicine and cancer clinic, cross-disciplinary research laboratories, a health policy think-tank, and community outreach and educational programs. The Ellison Medical Institute addresses pressing challenges in the prevention and treatment of cancer and other complex diseases, promoting innovation by integrating clinically driven science and applied engineering. The combination of our public-private partnerships, our bi-directional feedback between our clinic and research teams, and robust data enables us to accelerate advancements in research and patient care.  As a biomedical and technology hub, we collaborate with leading physicians, scientists and companies to propel vital research along the analytical pipeline to create clinically impactful interventions. Expert scientists, physicians, and thought leaders from around the world are invited to become visiting members at the Institute and collaborate with our multidisciplinary resident scientists. By uniting international experts from diverse disciplines under one roof, we aim to deliver insight and ingenuity to surmount hurdles that have been plaguing researchers and physicians for years. Learn More at: eitm.org

Dr. Pavani Chalasani was recruited to be Division Director for Hematology-Oncology at the George Washington University, George Washington Cancer Center (GWCC) and started in her new role 02/01/2023. She is also Co-Program Lead for Clinical Translational Oncology Program at GWCC. Her key research interest is in the development of biomarkers- imaging, blood-based or tissue. Dr. Chalasani is the Principal Investigator on several investigator-initiated, industry-sponsored, and co-operative group protocols. She is the medical oncology study chair on S1706, a NCTN study for patients with inflammatory breast cancer. Dr. Chalasani was awarded the prestigious NCI’s Clinical Cancer Investigator Team Leadership Award in 2020. She served as Program Director for Hematology-Oncology Fellowship program while at the UACC. She has received research funding from NIH/NCI, American Cancer Society, Better Than Ever and DOD.

Pavani Chalasani, MD completed her medical school at Gandhi Medical College in India and completed her Internship, Residency and Fellowship in Hematology-Oncology at the University of Arizona, Tucson. Dr. Chalasani was a part of the University of Arizona Cancer Center (UACC) as a faculty member focusing on breast cancer where she was very active in clinical and translational research.

Established in 2015, the George Washington University (GW) Cancer Center is a collaboration of the George Washington University, the GW Hospital, and the GW Medical Faculty Associates to expand GW’s efforts in the fight against cancer. The GW Cancer Center also incorporates all existing cancer-related activities at GW, with a vision to create a cancer-free world through groundbreaking research, innovative education, and equitable care for all. Located in the heart of Washington, D.C., the Center offers a dynamic, collaborative, and innovative model for cross-disciplinary collaboration and multidisciplinary patient care.

Sima Ehsani, M.D. serves as the Breast Clinical Research Team leader at the University of Arizona Cancer Center. Dr. Ehsani’s clinical expertise is breast oncology and treatment of breast cancer and management of complications related to that. She is a member of City of Hope Clinical Cancer Genomics Community of Practice and she sees women in High Risk Clinic for counseling and management of their increased risk for breast cancer. Dr. Ehsani’s research focus is treatment of breast cancer. She also has interest in breast cancer survivorship, cancer prevention and genetic risk assessment of cancer. She is part of Breast Disease-Oriented Team, through which multiple clinical trials in breast cancer are helping to find better and safer treatment options for patients with cancer.  Dr. Ehsani joined the faculty in the Department of Medicine, Division of Hematology/Oncology in 2016. She completed her fellowship at UW Carbone Cancer Center in Madison in 2013. She is board certified in internal medicine, hematology and medical oncology.  She earned her medical degree from Tehran University of Medical Sciences, Tehran, Iran;  she did an Internal Medicine Residency at St. Mary’s Hospital, Waterbury, CT.  Her Licensure & Board Certifications include an Internal Medicine Certification & Medical Oncology Certification, as well as Hematology and a City of Hope Intensive Course in Genetic Cancer Risk Assessment Certification. View her Research and Publications at: https://pubmed.ncbi.nlm.nih.gov/?term=Ehsani+S&cauthor_id=30158821

Dr. Carla Falkson is the Director of the Breast Oncology Clinical Research Program and Breast Cancer Service Line and Leader, Breast Cancer Unit in Medical Oncology at the UR Medicine Wilmot Cancer Institute. She is also the Medical Director of Pluta Cancer Center.

Dr. Falkson’s research is focused on developing innovative treatments for patients with breast cancer. For the past three decades, she has been actively involved in the development and planning of clinical trials using new agents, including genomic and other translational approaches such as circulating tumor DNA, to improve the selection of patients for specific treatments and thus improving the outcome for patients. As a seasoned investigator, she has led the Eastern Co-operative Group Research at her previous two institutions and now continues this legacy of excellence at the University of Rochester Medical Center.

Dr. Falkson’s philosophy is to understand the patient and his or her disease. She believes it is important to listen to a patient and hear their needs especially since their cancers, despite similarities, are all unique and need different approaches for treatment. She has a special interest in treating HER2 amplified (over-expressed), hormone receptor-positive breast cancer, and treatment modalities for optimal bone health in breast cancer patients.

She received her MBCHB from the University of Pretoria in 1982 and continued with Post-doctoral Training & Residency 1989 – 1994. She did a fellowship in Hematology/Oncology at University of Pretoria, and a fellowship in Medical Oncology at M.D. Anderson Cancer Center. Her awards include the, Unsung Hero Award from University of Alabama 2017.

Ruth O’Regan, M.D., chief of Hematology, Medical Oncology and Palliative Care at the University of Wisconsin, has been named the next Charles A. Dewey Professor and Chair of Medicine at the University of Rochester Medical Center’s School of Medicine and Dentistry, pending approval by the University Board of Trustees. Dr. O’Regan brings more than 20 years of experience in academic medicine and a distinguished history of research and publication to her new role.

Dr. O’Regan is an internationally recognized breast-cancer physician and researcher with particular expertise on breast cancers that are resistant to current therapies.

A native of Dublin, Ireland, O’Regan previously was a professor of hematology and medical oncology at Emory University, where she held the Louisa and Rand Glenn Family Chair in Breast Cancer Research. Additionally, O’Regan was the medical director at Glenn Family Breast Center of Emory University, director of the Breast Cancer Translational Research Program at the Winship Cancer Institute, and chief of hematology and medical oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital.

In her dedication to training the next generation of physicians, O’Regan served as vice chair for educational affairs in the department of hematology and medical oncology and as director of the hematology/oncology fellowship program at Emory University.

With a highly active research program focused on identifying mechanisms of resistance to breast-cancer therapies and development of new therapies, O’Regan has been principal investigator for numerous grants and clinical trials.

Her research group has made significant discoveries about the role of the PI3 Kinase-mTOR pathway in triple-negative breast cancer, showing that mTOR inhibition can sensitize breast-cancer cells to upstream growth-factor inhibitors. These discoveries resulted in a novel clinical trial for patients with metastatic breast cancer.

The University of Rochester Medical Center (URMC) is one of the nation’s leading academic medical centers. It forms the centerpiece of the University of Rochester’s health research, teaching and patient care missions.

The University of Rochester Medical Center is a private, coeducational, nonsectarian, and nonprofit research university.

The medical center includes Strong Memorial Hospital, the Eastman Institute for Oral Health, the University of Rochester School of Medicine and Dentistry, with its faculty practice (University of Rochester Medical Faculty Group), and the University of Rochester School of Nursing.

URMC was one of the first 12 academic medical centers to receive a Clinical and Translational Science Award from the National Institutes of Health and has been continually funded by this grant for a total of $86 million. The University also was awarded a one-in-the-nation $19 million grant to coordinate more than 50 of the top academic medical centers in the nation that are part of the Clinical and Translational Science Awards Program. Learn more at urmc.rochester.edu

Dr. William J. Gradishar, M.D., F.A.C.P. is professor of medicine in the division of hematology and medical oncology, department of medicine, at the Feinberg School Medicine at Northwestern University in Chicago, Illinois.

His research focuses on the development of the latest therapies for breast cancer treatment. He has published numerous articles in the area of breast cancer therapy, with a focus on new endocrine therapy and chemotherapy.

After receiving his medical degree from the University of Illinois Abraham School of Medicine in Chicago, he completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago. He then went on to a fellowship in medical oncology at the University of Chicago. He is Board Certified in Internal Medicine, Medical Oncology.

Dr. Gradishar is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He also serves as director of breast medical oncology, associate director of the Lynn Sage Comprehensive Breast Program, and program director of Northwestern University’s Hematology/Oncology Fellowship Training Program.

In addition, he is a Fellow of the American College of Physicians, a member of the American Association for Cancer Research and the American Federation for Clinical Research. He chairs the Oncology Training Program Committee of the American Society of Clinical Oncology (ASCO) and serves on numerous breast cancer committees in other major oncology organizations. In addition, he serves as a consultant to the Oncology Drug Advisory Committee of the FDA.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. In 1853, the founders purchased a 379-acre tract of land on the shore of Lake Michigan 12 miles north of Chicago. They established a campus and developed the land near it, naming the surrounding town Evanston in honor of one of the University’s founders, John Evans. After completing its first building in 1855, Northwestern began classes that fall with two faculty members and 10 students. Sixteen presidents have presided over Northwestern in the years since. The University has grown to include 12 schools and colleges, with additional campuses in Chicago and Doha, Qatar. Learn more at  www.northwestern.edu

Dr. Kaplan went to Medical School at the University of Rochester, NY. Did his Residency at the University of Washington, WA and a Fellowship with the National Cancer Institute/National Institutes of Health. Previously he was Chief Resident, Dept of Medicine: University of Washington, WA; Clinical Associate Professor, University of Washington; Clinical Professor of Medicine Brown University 1977-79; Adjunct Professor of Pharmacy, University of Rhode Island 1977-79; and Assistant Professor of Medicine, University of Washington 1979-1981. His Board Certifications include Internal Medicine and Oncology.

The primary focus of Dr. Kaplan’s research continues to be on breast cancer, although he is also continuing his work in hematological malignancies – cancers affecting blood, bone marrow and lymph nodes – and, more recently, in the area of targeted therapy for genomic mutation.

He has received multiple faculty teaching awards and a Swedish Physician Recognition Award, AOA and Dr. Kaplan was recognized in Seattle Metropolitan magazine’s annual Top Doctors and Nurse Practitioners feature.

As a Seattle-area leader in diagnosis, treatment and recovery since 1932, the Swedish Cancer Institute (SCI) cancer care network offers services to help you fight cancer – and win. Our team includes a host of oncologists – doctors focused exclusively on the care and treatment of cancer, using medication, radiation and other therapies. At our locations in and around the greater Seattle area, we work in a collaborative, multidisciplinary environment that focuses on the patient – not the disease. And even though we use some of the most advanced technologies and procedures, we also offer a wide range of complementary treatments and services that address your psychological, emotional and spiritual needs. The Swedish Cancer Institute has a new weapon in the fight against cancer. It’s called personalized medicine — the biggest news in cancer treatment in years.Learn more at http://www.swedish.org/services/cancer-institute

Dr. Michelle M. Loch, M.D., MACI is an Associate Professor of Medicine at Louisiana State University Health Sciences Center in New Orleans, where she has been on faculty since 2012. She completed her undergraduate studies at Virginia Commonwealth University, earned her medical degree from St. George’s University School of Medicine, and completed her Internal Medicine residency at the University of Virginia. She subsequently completed a Hematology/Oncology fellowship at Boston University Medical Center, where she also obtained a Master of Arts in Clinical Investigation.

Dr. Loch is a breast medical oncologist whose clinical practice focuses on breast cancer, with particular emphasis on clinical trials, healthcare disparities, symptom control, and quality of life. She is actively involved in SWOG, contributing to breast, symptom management, and survivorship committees, and serves as a principal investigator on both cooperative group and pharmaceutical-sponsored clinical trials at her institution. She also leads the breast cancer clinical trials disease group, supporting the development and advancement of innovative research to improve patient outcomes.

Since its inception some 75 years ago, the school of medicine has maintained a deep commitment to serving all patients, particularly the underserved. We are aligned with the LSUHSC Health Care Services Division which consists of nine hospitals throughout the state. Through this important relationship, our faculty and house staff provide quality medical care to the residents of Louisiana regardless of income or insurance coverage. Simultaneously, our partnerships with the LSU Healthcare Network and local private hospitals supply outstanding care to a growing population of private patients. These wide ranging medical services support the people of our state while providing the backdrop for a broad and comprehensive clinical education for our students and residents in training. In addition, LSU is home to the Stanley S. Scott Cancer Center (SSSCC) a multidisciplinary organization whose researchers and clinicians apply a range of expertise to cancer research, education, and patient care.
Learn more at  LSUHSC

Dr. Terry Ng is an Assistant Professor at the University of Ottawa and a Clinician-Investigator in the Department of Medicine. He received his Bachelor of Health Sciences from McMaster University and his MD from the University College Cork. Dr. Ng completed Internal Medicine and Medical Oncology training at the University of Ottawa, followed by an advanced fellowship in Investigational Cancer Therapeutics at the University of Colorado, a National Cancer Institute-designated comprehensive cancer centre.

Dr. Ng’s research interests have focused on treatment-related adverse events. He is the co-Principal Investigator on a multi-center study of early-onset pulmonary toxicity associated with Brigatinib. He is also a co-investigator on a trial funded by the Canadian Breast Cancer Foundation to better address chemotherapy-induced nausea and vomiting. He will be heavily involved in the REaCT pragmatic trials program, which aims to answer real-world, clinical questions in a cost-effective manner.

The Ottawa Hospital Research Institute is the research arm of The Ottawa Hospital – one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and annual budget of over $1.2 billion. We rank fourth out of more than 600 Canadian hospitals for competitive, peer-reviewed grants from the prestigious Canadian Institutes of Health Research. The Ottawa Hospital Research Institute’s vision is to give patients and their loved ones new hope through research that is making tomorrow’s health care possible today. The focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, they deliver specialized care to the Eastern Ontario region, but the techniques and research discoveries are adopted around the world.

Jacklyn Nemunaitis, M.D. is Assistant Professor, Department of Internal Medicine, Division of Hematology/Oncology

(SOM – Internal Medicine, CC – Breast Cancers, CC – Medical Oncology, SOM – Comprehensive Cancer Center)

She received her Medical Education at McGovern Medical School University of Texas Medical Branch and has Board Certification in Hematology, Internal Medicine and Medical Oncology.  She is a faculty member at the University of New Mexico Comprehensive Cancer Center with a research focus in breast cancer and clinical education. She has been a member of the breast working group at UNMCCC since 2019 and her research focus is in the area of cardiotoxicity and patient survivorship. In a collaboration with cardiology, they are retrospectively reviewing the rates of cardiotoxicity in Native American patients treated for cancer. In a collaboration with population sciences, they are investigating the benefit of an exercise intervention in improving pain for young, Hispanic breast cancer survivors. Dr. Nemunaitis is also very passionate about medical education and serves as Associate Program Director for the Hematology/Oncology Fellowship Program and has instituted several IRB-approved interventions to enhance career development for fellows and junior faculty.

The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. . The 130 cancer research scientists affiliated with the UNMCCC were awarded almost $60 million in federal and private grants and contracts for cancer research projects and published 301 high quality publications. Promoting economic development, they filed more than 30 new patents in FY16, and since 2010, have launched 11 new biotechnology start-up companies. Scientists associated with the UNMCCC Cancer Control & Disparities have conducted more than 60 statewide community-based cancer education, prevention, screening, and behavioral intervention studies involving more than 10,000 New Mexicans. Finally, the physicians, scientists and staff have provided education and training experiences to more than 230 high school, undergraduate, graduate, and postdoctoral fellowship students in cancer research and cancer health care delivery. Learn more at  cancer.unm.edu

Dr. Pusztai is Professor of Medicine at Yale University and Chief of the Breast Medical Oncology Section at the Yale Cancer Center. He is also Co-Director of the Cancer Center Genomics and Genetics Program.

He received his medical degree from the Semmelweis University of Medicine in Budapest, and his D.Phil. degree from the University of Oxford in England. He was a Fellow at University of Texas Anderson Cancer Center in Medical Oncology and an intern and resident at University of Rochester St. Mary’s Hospital, Internal Medicine.

His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical and epidemiological risk characteristics. He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and have shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. His group has also developed new bioinformatics tools to integrate information from across different data platforms in order to define the molecular pathways that are significantly disturbed in individual cancers and could provide the bases for future individualized treatment strategies. He made important contributions to clarify the clinical value of neoadjuvant chemotherapy in different breast cancer subtypes.

Dr. Pusztai is also principal investigator of several clinical trials investigating new drugs and potential response markers. He has published over 200 manuscripts in high impact medical journals and is the Clinical Editor of the British Journal of Cancer, Member of the Scientific Advisory Board of the Breast Cancer Research Foundation, Member of the Breast Cancer Steering Committee of the NCI and Co-Chair of the Trans-ALTTO Committee that oversees the translational research projects of tissues collected during two larger randomized clinical trials (ALTTO and NeoALTTO). He is a member of the BCRF Scientific Advisory Board and the Chair of the Data Safety Monitoring Committee of the OPTIMA trial.

Yale Medical Group (YMG) is one of the largest academic multispecialty group practices in the United States. Our physicians are the clinical faculty for the Yale School of Medicine (YSM). We have over 1,000 practicing physicians, more than 100 specialties and subspecialties, 24/7 on-site and on-call coverage for numerous services, a reputation as a major referral center for Greater New Haven, Connecticut, and New England. We provide compassionate, individualized care to both adult and pediatric patients in a comfortable, professional environment. We listen carefully and provide explanations and answers while encouraging patients to participate in all medical decisions. We work in teams with specially trained nurses, social workers, technologists and other caregivers to support patients and family members before, during and after their visits. Learn more at: http://yalemedicalgroup.org/about/index.aspx#page1

Dr. Alison Stopeck is Chief, Division of Hematology/Oncology, Professor, Department of Internal Medicine Associate & Director for Translational Research, Stony Brook Cancer Center. She obtained her MD degree from Columbia University College of Physicians and Surgeons, NY. She did her residency in Internal Medicine, at Columbia Presbyterian Medical Center, NY and a Fellowship in Hematology/Oncology at Cornell University Medical College, NY. She is board certified from the American Board of Internal Medicine, subspecialties in Hematology and Medical Oncology.

As for Dr. Stopeck’s research interests, she is currently involved in clinical trials targeting patients with breast cancer, who are receiving chemotherapy. Dr. Stopeck is the principal or collaborating investigator on multiple clinical trials involving novel agents, prognostic markers and predictors of response in breast cancer patients, as well as supportive care and survivorship issues in breast cancer. Dr. Stopeck has numerous publications in medical journals and textbooks, including the New England Journal of Medicine and the Journal of Clinical Oncology. She acts as an Associate Editor for the American Journal of Medicine and is an ad hoc reviewer for several journals. She has been a funded investigator from the NCI for over a decade.

Her honors and awards include:

• Who’s Who in America-Professional Edition
• 2014 – Best Doctors in America, Woodward/White, Inc.
• 2009 – America’s Top Doctor for Cancer

Long Island’s premier academic medical center, Stony Brook Medicine represents Stony Brook University’s entire medical enterprise and integrates Stony Brook’s health-related initiatives: education, research and patient care. It encompasses Stony Brook University Hospital, the five Health Sciences schools � Dental Medicine, Health Technology and Management, Medicine, Nursing and Social Welfare � as well as the major centers and institutes, programs and more than 50 community-based healthcare settings throughout Suffolk County. Learn more at https://www.stonybrookmedicine.edu/patientcare

Kari Wisinski, MD is an Assoc. Professor (CHS) at Univ of Wisconsin School of Medicine Hematology/Oncology Division

Dr. Kari Wisinski is a medical oncologist with UW School of Medicine and Public Health and the Carbone Cancer Center in Madison, Wisconsin, and is a member of the UW Health Breast Center.

Dr. Wisinski obtained her medical degree from Washington University School of Medicine in 2001. She then completed internal medicine residency at the University of Colorado Health Sciences Center, followed by a combined hematology and oncology fellowship at Northwestern University. She is board certified in hematology and medical oncology.

In 2008, she joined the University of Wisconsin School of Medicine and Public Health in the Division of Hematology/Oncology. Her clinical expertise involves the care of patients with breast cancer. Dr. Wisinski’s research is focused on designing and running clinical trials testing targeted agents for breast cancer, with a particular focus on phase I trials and triple negative breast cancer. Dr. Wisinski is also co-Director of the Wisconsin Oncology Network, a statewide medical oncology research group and co-Leader of the Big Ten Cancer Research Consortium Breast Cancer Working Group.

UW Health consists of the academic health care entities of the University of Wisconsin-Madison: UW Medical Foundation, UW Hospital and Clinics and UW School of Medicine and Public Health. UW Health is also home to American Family Children’s Hospital and UW Carbone Cancer Center. Our expert doctors are at the forefront of research, developing new treatments and training the next generation of physicians. Together with other health care professionals, they serve the health needs of Wisconsin, and beyond. By combining our resources into one system, we are able to offer a network of primary and specialty care clinics throughout southcentral Wisconsin and beyond.

This network provides access to more than 1,200 primary and specialty care physicians who are leaders in their fields, as well as the opportunity to be treated at University of Wisconsin Hospital and Clinics, frequently cited in published rankings of the finest academic medical centers. Learn more at:  http://www.uwhealth.org/about-uwhealth/main/10730

Dr. Douglas Yee is Professor of Medicine and Pharmacology and the Cancer Center Director at the Masonic Cancer Center, University of Minnesota. He received his MD in 1981 from the University of Chicago Pritzker School of Medicine. He received his internal medicine training and was Chief Medical Resident at the University of North Carolina. His medical oncology training was done at the National Cancer Institute in Bethesda, Maryland. Prior to coming to Minnesota, he held faculty positions at Georgetown University Medical Center and the University of Texas Health Science Center at San Antonio. Dr. Yee holds the John H. Kersey Chair in Cancer Research. He was previously co-leader of the Women’s Cancer Program. Dr Yee specializes in Medical Oncology and Breast Cancer.

The Masonic Cancer Center was founded in 1991. It is part of the University’s Academic Health Center, which also includes the Medical School, School of Dentistry, School of Nursing, College of Pharmacy, School of Public Health and College of Veterinary Medicine. The Masonic Cancer Center’s research partners include the University’s Stem Cell Institute, Center for Immunology, the Center for Magnetic Resonance Imaging, the Clinical and Translational Science Center and the Physical Sciences in Oncology Center; and its clinical research and treatment partners include University of Minnesota Health Cancer Care, University of Minnesota Medical Center, and University of Minnesota Masonic Children’s Hospital. The Masonic Cancer Center, University of Minnesota is designated by the National Cancer Institute as a comprehensive cancer center. The NCI awards this highest-level designation only to institutions that make ongoing, significant advances in cancer research, treatment, and education. Masonic Cancer Center is part of a 47-member group of cancer centers in the United States to hold the comprehensive designation, and the only one in the greater Twin Cities region. Learn more at: http://www.med.umn.edu/about